COVID-19

Michael Hogue joins Ed Cohen and John Beckner to dig deeper into vaccine hesitancy, boosters, and other topics in the immunization space.

Structural changes to the COVID-19 virus highlight the need to expand the research efforts.

The difference between individuals who were vaccinated and had the infection were higher at different intervals than for those who were unvaccinated.

A new poll shows that this year 64% of individuals between aged 50 and 64 years say they already got or are likely to get their influenza shots up from 54% last year.

In addition to the prevention of disease in children, COVID-19 vaccination can also limit disruptions in school attendance so that children can participate safely in school and other activities.

Study shows that about half the pediatric cases were symptomatic compared with 88% for individuals aged 18 years and older.

Pharmacists and technicians have an opportunity to prove their value as immunizers now that the Pfizer-BioNTech COVID-19 vaccine has been authorized for use in children ages 5 to 11.

The results also showed they were nearly 20 times more effective at preventing hospitalizations from the virus for individuals older than 65 than a prior infection alone.

The results of a study show that individuals who received 3 doses of the BNT162b2 vaccine had a 93% lower risk of hospitalization than those who had just 2.

Among those who were infected with the delta variant (126), 25% were fully immunized and 38% were unvaccinated, study results show.

Mathematical model from Penn State shows an alternative to business shutdowns and stay-at-home orders that are unsustainable over time.

Linda Mendonça, DNP, RN, PHNA-BC, president of the National Association of School Nurses, discusses a new poll released by the COVID-19 Vaccine Education and Equity Project and the National Association of School Nurses about parents’ plans to vaccinate their school-aged children.

These biomarkers may be able to control inflammation in the body once infected with COVID-19 and can help determine the seriousness of the infection, the researchers noted.

Investigators reviewed 65 analyses published in the Journal of Affective Disorders showing that by mid-2020 signs were comparable to pre-COVID-19 levels.

Pfizer and BioNTech have also announced that they will be providing the US government with an additional 50 million of the 10 μg doses, with an expected delivery by April 30, 2022.

The investigators said this study is one of the first to measure the impairment and impact of post-acute COVID syndrome on patients.

The investigators evaluated and compared the immune responses induced by the 3 vaccines over the course of an 8-month follow-up period.

In addition, some parents may still be unvaccinated, so counseling them on the safety and efficacy of the vaccines is important.

No timetable was set for the FDA to decide on an official EUA designation for the Pfizer-BioNTech vaccine in children 5 to 11 years of age, however a decision is expected within the next few days.

In accordance with the new guidance, individuals may choose to receive a dose different from the one they received for their initial series.

Patients undergoing chemotherapy had lower COVID-19 antibody levels than patients undergoing targeted therapy following vaccination.

Gary Locke, former governor of Washington state, US Secretary of Commerce, and ambassador to China, discusses the World Trade Organization's TRIPS Council, which recently met to assess the elimination of IP protections for COVID-19 vaccines, diagnostics, and medical devices.

Data show 99.2% of children 5 to 11 years of age achieved a seroresponse by 1 month after completing the 2-dose vaccine series.

The CDC recommends booster doses of Moderna’s COVID-19 vaccine and Johnson & Johnson’s single-shot COVID-19 vaccine for eligible individuals.

The investigators found that the rate of preterm birth in pregnant women who tested positive for SARS-CoV-2 was a function of the severity of infection.